<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81696">
  <stage>Registered</stage>
  <submitdate>15/11/2006</submitdate>
  <approvaldate>23/11/2006</approvaldate>
  <actrnumber>ACTRN12606000481572</actrnumber>
  <trial_identification>
    <studytitle>Efficacy of Vitamin C treatment for children with Charcot-Marie-Tooth disease type 1A</studytitle>
    <scientifictitle>Efficacy of ascorbic acid supplementation in children with Charcot-Marie-Tooth disease type 1A to improve muscle strength and peripheral nerve function</scientifictitle>
    <utrn />
    <trialacronym>vitCmt</trialacronym>
    <secondaryid>Nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Children with Charcot-Marie-Tooth disease type 1A</healthcondition>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other human genetics and inherited disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Experimental group: Daily oral ascorbic acid supplementation for 12 months as per the established age-specific tolerable upper intake levels of ascorbic acid (US Food and Nutrition Board Institute of Medicine, 2000). </interventions>
    <comparator>Control group: Daily oral placebo for 12 months.</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>a) Isometric muscle strength of the foot and ankle</outcome>
      <timepoint>Measured at baseline and 12 months</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>b) Disease progression via nerve conduction studies of the median nerve</outcome>
      <timepoint>Measured at baseline and 12 months</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Neurophysiological studies of the median nerve, isometric hand strength, functional ability, health-related quality of life</outcome>
      <timepoint>Measured at baseline and at 12-months follow-up</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Diagnosis of Charcot-Marie-Tooth disease type 1A. </inclusivecriteria>
    <inclusiveminage>2</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>16</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Pregnancy; glucose-6-phosphate dehydrogenase deficiency; hereditary hemochromatosis; thalassemia; polycythemia; leukaemia or sideroblastic anaemia; sickle cell anaemia; acute foot injuries and recent foot surgery; inflammatory arthritis; diabetes.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Central randomisation by telephone</concealment>
    <sequence>Permuted block randomisation stratified for centre and age</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>Blinded subjects, therapists and assessors</designfeatures>
    <endpoint>Safety/efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>15/01/2007</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>80</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>The Children's Hospital at Westmead</primarysponsorname>
    <primarysponsoraddress>Locked Bag 4001, Westmead NSW 2145 Australia</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>University</fundingtype>
      <fundingname>The University of Sydney</fundingname>
      <fundingaddress>Locked Bag 4001, Westmead NSW 2145 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Institute for Neuromuscular Research</fundingname>
      <fundingaddress>Locked Bag 4001, Westmead NSW 2145 Australia</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Government body</sponsortype>
      <sponsorname>The Children's Hospital at Westmead</sponsorname>
      <sponsoraddress>Locked Bag 4001, Westmead NSW 2145 Australia</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this trial is to determine the effect of high-dose vitamin C on muscle strength, nerve function, gross motor coordination and health-related quality of life in children with Charcot-Marie-Tooth disease type 1A.

We hypothesise that muscle strength,  nerve function, gross motor coordination and health-related quality of life will be greater in children with Charcot-Marie-Tooth disease type 1A who receive dietary vitamin C supplementation compared to children receiving the placebo.</summary>
    <trialwebsite />
    <publication>Burns J. Ouvrier RA. Yiu EM. Joseph PD. Kornberg AJ. Fahey MC. Ryan MM. Ascorbic acid for CharcotMarieTooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurology. 8 (6) 537-544, 2009.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>The Children's Hospital at Westmead</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>2006/056</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Royal Children's Hospital, Melbourne</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec>26144</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr. Joshua Burns</name>
      <address>Institute for Neuromuscular Research
The Children's Hospital at Westmead 
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451228</phone>
      <fax>+61 2 98451317</fax>
      <email>joshuab2@chw.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr. Joshua Burns</name>
      <address>Institute for Neuromuscular Research
The Children's Hospital at Westmead 
Locked Bag 4001
Westmead NSW 2145</address>
      <phone>+61 2 98451228</phone>
      <fax>+61 2 98451317</fax>
      <email>joshuab2@chw.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>